Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vildagliptin + vitamin D
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
vildagliptin + vitamin D is a combination therapy investigated for the treatment of non-alcoholic fatty liver disease (NAFLD). It consists of vildagliptin, a small molecule dipeptidyl peptidase-4 (DPP-4) inhibitor, and vitamin D. Vildagliptin works by preventing the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhances insulin secretion and improves glycemic control. Vitamin D is included to potentially improve insulin sensitivity, lipid metabolism, and reduce liver inflammation and fibrosis. The combination was studied by Ziv Hospital in a Phase 2 clinical trial (NCT01083992) involving patients with NAFLD to evaluate its impact on liver histopathology and metabolic markers.
- Brand names
- Galvus
- Other names
- vitagliptinvildagliptin + vitamin DGalvus + vitamin D
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on vildagliptin + vitamin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vildagliptin + vitamin D.